Review





Similar Products

human hepatocellular carcinoma tissue section microarray  (U.S Biomax Inc)
90
U.S Biomax Inc human hepatocellular carcinoma tissue section microarray
WNT5A may link SEL1L-HRD1 ERAD to hepatic proliferation (A and B) Volcano plot (A) and tabular form (B) of proteomics data obtained via TMT-LC/MS analysis of hepatic ER isolated from 2- to 3-months-old mice (n = 3 per group). Lines mark p = value 0.05 (horizontal) or 2-fold changes (vertical). (C–F) Western blot analysis of ER and non-ER fractions from livers of 2-month-old mice (n = 3 per group) (C, black and red arrows mark WNT5A mobility shift), hepatocellular carcinoma and normal liver tissue from the DEN-HFD liver cancer model (n = 2 per group, 2 independent repeats) (D), livers of 10-week-old mice 48-h post partial hepatectomy (n = 3 per group) (E), livers from chronic CCL4 treatment (n = 2 per group) (F). (G) Western blot analysis normal liver and tumor tissues from the year-long-HFD experiment (n = 3 per group). (H and I) Hepatic cDNA <t>microarray</t> analyses of 9-week-old Sel1L Alb livers compared to Sel1L f/f livers: (H) KEGG pathway for Gene Set Enrichment Analysis (GSEA) from differentially expressed hepatic genes with p < 0.05 and fold change >1.29, and (I) Heatmap of proliferation-associated genes as a logarithm of fold change in Sel1L Alb and Hrd1 Alb livers as compared to Sel1L f/f and Hrd1 f/f livers, respectively (n = 3 per group). (J) Western blot analysis of HepG2 and Huh7 cells treated with 500 ng/mL recombinant WNT5A protein for 30 h (2 independent repeats). (K) Western blot analysis of Sel1L f/f and Sel1L Alb livers 2 weeks after i.v. injection of AAV8 expressing shRNA targeting Wnt5A or luciferase control (n = 2–3 per group). Quantitation shown below each blot. Calnexin, ER fraction control; HSP90, loading and non-ER controls. Values, mean ± SEM; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001 by Student’s t test.
Human Hepatocellular Carcinoma Tissue Section Microarray, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human hepatocellular carcinoma tissue section microarray/product/U.S Biomax Inc
Average 90 stars, based on 1 article reviews
human hepatocellular carcinoma tissue section microarray - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


WNT5A may link SEL1L-HRD1 ERAD to hepatic proliferation (A and B) Volcano plot (A) and tabular form (B) of proteomics data obtained via TMT-LC/MS analysis of hepatic ER isolated from 2- to 3-months-old mice (n = 3 per group). Lines mark p = value 0.05 (horizontal) or 2-fold changes (vertical). (C–F) Western blot analysis of ER and non-ER fractions from livers of 2-month-old mice (n = 3 per group) (C, black and red arrows mark WNT5A mobility shift), hepatocellular carcinoma and normal liver tissue from the DEN-HFD liver cancer model (n = 2 per group, 2 independent repeats) (D), livers of 10-week-old mice 48-h post partial hepatectomy (n = 3 per group) (E), livers from chronic CCL4 treatment (n = 2 per group) (F). (G) Western blot analysis normal liver and tumor tissues from the year-long-HFD experiment (n = 3 per group). (H and I) Hepatic cDNA microarray analyses of 9-week-old Sel1L Alb livers compared to Sel1L f/f livers: (H) KEGG pathway for Gene Set Enrichment Analysis (GSEA) from differentially expressed hepatic genes with p < 0.05 and fold change >1.29, and (I) Heatmap of proliferation-associated genes as a logarithm of fold change in Sel1L Alb and Hrd1 Alb livers as compared to Sel1L f/f and Hrd1 f/f livers, respectively (n = 3 per group). (J) Western blot analysis of HepG2 and Huh7 cells treated with 500 ng/mL recombinant WNT5A protein for 30 h (2 independent repeats). (K) Western blot analysis of Sel1L f/f and Sel1L Alb livers 2 weeks after i.v. injection of AAV8 expressing shRNA targeting Wnt5A or luciferase control (n = 2–3 per group). Quantitation shown below each blot. Calnexin, ER fraction control; HSP90, loading and non-ER controls. Values, mean ± SEM; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001 by Student’s t test.

Journal: iScience

Article Title: SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer

doi: 10.1016/j.isci.2022.105183

Figure Lengend Snippet: WNT5A may link SEL1L-HRD1 ERAD to hepatic proliferation (A and B) Volcano plot (A) and tabular form (B) of proteomics data obtained via TMT-LC/MS analysis of hepatic ER isolated from 2- to 3-months-old mice (n = 3 per group). Lines mark p = value 0.05 (horizontal) or 2-fold changes (vertical). (C–F) Western blot analysis of ER and non-ER fractions from livers of 2-month-old mice (n = 3 per group) (C, black and red arrows mark WNT5A mobility shift), hepatocellular carcinoma and normal liver tissue from the DEN-HFD liver cancer model (n = 2 per group, 2 independent repeats) (D), livers of 10-week-old mice 48-h post partial hepatectomy (n = 3 per group) (E), livers from chronic CCL4 treatment (n = 2 per group) (F). (G) Western blot analysis normal liver and tumor tissues from the year-long-HFD experiment (n = 3 per group). (H and I) Hepatic cDNA microarray analyses of 9-week-old Sel1L Alb livers compared to Sel1L f/f livers: (H) KEGG pathway for Gene Set Enrichment Analysis (GSEA) from differentially expressed hepatic genes with p < 0.05 and fold change >1.29, and (I) Heatmap of proliferation-associated genes as a logarithm of fold change in Sel1L Alb and Hrd1 Alb livers as compared to Sel1L f/f and Hrd1 f/f livers, respectively (n = 3 per group). (J) Western blot analysis of HepG2 and Huh7 cells treated with 500 ng/mL recombinant WNT5A protein for 30 h (2 independent repeats). (K) Western blot analysis of Sel1L f/f and Sel1L Alb livers 2 weeks after i.v. injection of AAV8 expressing shRNA targeting Wnt5A or luciferase control (n = 2–3 per group). Quantitation shown below each blot. Calnexin, ER fraction control; HSP90, loading and non-ER controls. Values, mean ± SEM; ∗, p < 0.05; ∗∗, p < 0.01; ∗∗∗, p < 0.001 by Student’s t test.

Article Snippet: Human hepatocellular carcinoma tissue section microarray was obtained from US Biomax, Inc. (HLivH180Su14).

Techniques: Liquid Chromatography with Mass Spectroscopy, Isolation, Western Blot, Mobility Shift, Microarray, Recombinant, Injection, Expressing, shRNA, Luciferase, Quantitation Assay

Journal: iScience

Article Title: SEL1L-HRD1 ER-associated degradation suppresses hepatocyte hyperproliferation and liver cancer

doi: 10.1016/j.isci.2022.105183

Figure Lengend Snippet:

Article Snippet: Human hepatocellular carcinoma tissue section microarray was obtained from US Biomax, Inc. (HLivH180Su14).

Techniques: Western Blot, Plasmid Preparation, Microarray, Recombinant, Purification, Mutagenesis, Software, Expressing